AZI demonstrates strong financial ratio compliance across AAOIFI, MSCI, and S&P standards, with debt at 28.28%, liquidity at 0.76%, and non-compliant income at 0.77%. However, due to exclusion from all major Shariah indices stemming from small market capitalization and liquidity constraints, the overall status is NON_COMPLIANT. Business activities in biopharmaceuticals appear permissible, but limited data on subsidiaries and segments warrants caution. Purification is required at 0.77% for minor interest income. Investors should monitor for index eligibility improvements as the company scales.